Sveriges Riksbank
CONDITIONS FOR RIKSBANK AUCTIONS GOVERNMENT BONDS
CONDITIONS FOR RIKSBANK AUCTIONS GOVERNMENT BONDS
| Bid procedure, 2025-04-04 | |
| Bonds | SWEDISH GOVERNMENT: 1060. SE0009496367. 2028-05-12 SWEDISH GOVERNMENT: 1053, SE0002829192, 2039-03-30 |
| Bid date | 2025-04-04 |
| Bid times | 09.00-10.00 (CET/CEST) on the Bid date |
| Offered volume (corresponding nominal amount) | 1060: 1500 million SEK +/-1500 million SEK 1053: 1500 million SEK +/-1500 million SEK |
| Highest permitted bid volume (corresponding nominal amount) | 1060: 1500 million SEK per bid 1053: 1500 million SEK per bid |
| Lowest permitted bid volume (corresponding nominal amount) | SEK 10 million per bid |
| Expected allocation time | Not later than 10.15 (CET/CEST) on the Bid date |
| Delivery and payment date | 2025-04-08 |
| Settlement amount | To be paid to the Riksbank's account in Euroclear Sweden AB's securities settlement system SWIFT: VPCSSESSXXX Account: 1 4948 6383 CTM BIC: RIKSSESS ALERT acronym: RIKSBANK |
Stockholm, 2025-03-28
This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
ProvaDent2.4.2025 03:18:11 CEST | Press release
ProvaDent Reviews (DENTIST INVESTIGATED): Can This Oral Probiotic Really Strengthen Teeth and Reverse Years of Damage?
Tenaris SA2.4.2025 00:05:53 CEST | Press release
Tenaris Files 2024 Annual Report / Annual Report on Form 20-F, and Convenes the Annual General Meeting of Shareholders and an Extraordinary General Meeting of Shareholders
INVENTIVA1.4.2025 23:00:00 CEST | Press release
Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis
Respilean1.4.2025 22:30:10 CEST | Press release
Respilean Review (BREAKING NEWS): Why Thousands Are Calling It the Natural Lung Breakthrough of 2025
nCino, Inc.1.4.2025 22:06:00 CEST | Press release
nCino Reports Fourth Quarter and Fiscal Year 2025 Financial Results
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom